Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-05-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/8/1/e002323.full |
| _version_ | 1828780069987811328 |
|---|---|
| author | Georg Schett Bernhard Manger Thomas Harrer Filippo Fagni Arnd Kleyer Larissa Valor-Méndez Karin Manger David Simon Koray Tascilar Katja Schmidt Daniela Bohr Fabian Hartmann |
| author_facet | Georg Schett Bernhard Manger Thomas Harrer Filippo Fagni Arnd Kleyer Larissa Valor-Méndez Karin Manger David Simon Koray Tascilar Katja Schmidt Daniela Bohr Fabian Hartmann |
| author_sort | Georg Schett |
| collection | DOAJ |
| first_indexed | 2024-12-11T17:11:37Z |
| format | Article |
| id | doaj.art-468998900954473db4fffbc2547414a5 |
| institution | Directory Open Access Journal |
| issn | 2056-5933 |
| language | English |
| last_indexed | 2024-12-11T17:11:37Z |
| publishDate | 2022-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj.art-468998900954473db4fffbc2547414a52022-12-22T00:57:30ZengBMJ Publishing GroupRMD Open2056-59332022-05-018110.1136/rmdopen-2022-002323Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccinationGeorg Schett0Bernhard Manger1Thomas Harrer2Filippo Fagni3Arnd Kleyer4Larissa Valor-Méndez5Karin Manger6David Simon7Koray Tascilar8Katja Schmidt9Daniela Bohr10Fabian Hartmann1122 Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, GermanyDepartment of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universiätsklinikum Erlangen, Erlangen, GermanyDepartment of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universiätsklinikum Erlangen, Erlangen, GermanyDepartment of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universiätsklinikum Erlangen, Erlangen, GermanyDepartment of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universiätsklinikum Erlangen, Erlangen, Germany1 Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, GermanyRheumatology Practice Bamberg, Erlangen, GermanyDepartment of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universiätsklinikum Erlangen, Erlangen, GermanyDepartment of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universiätsklinikum Erlangen, Erlangen, GermanyDepartment of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universiätsklinikum Erlangen, Erlangen, GermanyDepartment of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universiätsklinikum Erlangen, Erlangen, GermanyDepartment of Internal Medicine 3, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germanyhttps://rmdopen.bmj.com/content/8/1/e002323.full |
| spellingShingle | Georg Schett Bernhard Manger Thomas Harrer Filippo Fagni Arnd Kleyer Larissa Valor-Méndez Karin Manger David Simon Koray Tascilar Katja Schmidt Daniela Bohr Fabian Hartmann Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination RMD Open |
| title | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_full | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_fullStr | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_full_unstemmed | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_short | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_sort | effects of casirivimab imdevimab on systemic and mucosal immunity against sars cov 2 in b cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| url | https://rmdopen.bmj.com/content/8/1/e002323.full |
| work_keys_str_mv | AT georgschett effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT bernhardmanger effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT thomasharrer effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT filippofagni effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT arndkleyer effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT larissavalormendez effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT karinmanger effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT davidsimon effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT koraytascilar effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT katjaschmidt effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT danielabohr effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT fabianhartmann effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination |